Clinical trial · Interventional
PSMA Specific [68Ga]-P137 Peptide Probe for PET Imaging in Prostate Cancer
NCT04560725CI-TRIAL-00079897unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To study the radioactive uptake of \[68Ga\]P137 in the lesion sites of PCa patients and evaluate the ability of \[68Ga\]P137 to detect PSMA overexpression in PCa patients (especially those with recurrent or advanced PCa).
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 11C-Choline | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- [68Ga] P137
- description
- Imaging cohort. All study participants will be allocated to this arm (single-arm study).Study participants will undergo \[68Ga\]P137 PET/CT scans.
- interventionNames
- Drug: 11C-Choline
Primary outcomes (1)
- measure
- SUV
- timeFrame
- 2 years
- description
- The uptake of the tracer in the primary and metastatic tumor lesions by measuring standardized uptake value（SUV）on PET/CT
Secondary outcomes (1)
- measure
- ROC
- timeFrame
- 2 years
- description
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Men over 18 years of age need to undergo \[68Ga\]P137 PET/CT examination for suspected prostate cancer. * The patients can fully understand and voluntarily participate in this experiment, and sign the informed consent. Exclusion Criteria: * Significant hepatic or renal dysfunction; * Patients with malignant tumors other than prostate cancer within 2 years; * Ready to pregnant; * The patient can not tolerate all clinical tests.
References
Publications (1)
- DERIVEDDuan X, Cao Z, Zhu H, Liu C, Zhang X, Zhang J, Ren Y, Liu F, Cai X, Guo X, Xi Z, Pomper MG, Yang Z, Fan Y, Yang X. 68Ga-labeled ODAP-Urea-based PSMA agents in prostate cancer: first-in-human imaging of an optimized agent. Eur J Nucl Med Mol Imaging. 2022 Feb;49(3):1030-1040. doi: 10.1007/s00259-021-05486-x. Epub 2021 Aug 28. PMID 34453203